retatrutide mechanism glp-1 gip glucagon triple agonist review 2024 2025 Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

Adipose Tissue Immunomodulation As previously discussed in Chapter 2, exposure to obesogenic compounds, mainly plasticisers, was demonstrated to dysregulate the secretion of a panoply of cyto/chemokines by adipose tissue, which includes the upregulation of proinflammatory mediators linked to the prostate carcinogenic process, namely several ILs (IL-1, 6, 8, 17A, 18), TNF-, MCP-1 and CCL20 [174, 175, 177, 178, 203]

Remember, the key to staying consistent is not perfection

As well, in real-world scenarios, such as described by Brindisi et al, it is mentioned a reduction in pleasure and taste perception in overweight and people with obesity with poor type 2 diabetes control, probably by lowering the detection threshold of sweet flavors, becoming more sensitive to them, resulting in aversion for this flavor (175)

Another reported effect has been growth of lymphoid tissue (specially acromegaly and tonsillar hypertrophy), renal enlargement (with normal kidney function) and in rare cases facial coarsening of features and incremented hair growth [264]